Staufen
Germany
31
2025-06-26
The entities that hold a legal rights for patent applications filed by inventor Ahlheim Markus:
Markus Ahlheim from Staufen, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
Octreotide Depot Formulation with Constantly High Exposure Levels
#2 | 2025-03-13SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
#3 | 2024-03-14Octreotide Depot Formulation with Constantly High Exposure Levels
#4 | 2022-09-22SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
#5 | 2021-06-03Octreotide Depot Formulation with Constantly High Exposure Levels
#6 | 2020-07-02SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
#7 | 2019-07-11Octreotide depot formulation with constantly high exposure levels
#8 | 2018-05-24Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-co-glycolide Polymers
#9 | 2018-02-08OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS
#10 | 2017-05-25OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS
#11 | 2016-05-05Sustanined Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers
#12 | 2016-03-31Octreotide depot formulation with constantly high exposure levels
#13 | 2015-02-05Sustained Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers
#14 | 2014-12-11Octreotide Depot Formulation with Constantly High Exposure Levels
#15 | 2013-05-16Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration
#16 | 2013-01-10Injectable depot formulation comprising crystals of iloperidone
#17 | 2012-09-06Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
#18 | 2012-08-23MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES
#19 | 2012-06-21Injectable depot formulation comprising crystals of iloperidone
#20 | 2011-10-27Octreotide depot formulation with constantly high exposure levels
#21 | 2011-09-01Injectable depot formulation comprising crystals of iloperidone
#22 | 2011-01-06SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND THREE LINEAR POLYLACTIDE-CO-GLYCOLIDE POLYMERS
#23 | 2010-10-28Microparticles comprising somatostatin analogues
#24 | 2010-10-21OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS
#25 | 2010-09-16Organic compounds
#26 | 2010-08-03Organic compounds
#27 | 2009-04-16INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE
#28 | 2009-01-01Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-Co-Glycolide Polymers
#29 | 2007-09-13Microparticles comprising somatostatin analogues
#30 | 2006-08-24Parenteral formulation of mycophenolic acid, a salt or prodrug thereof
#31 | 2005-11-10Injectable depot formulation comprising crystals of iloperidone
30087 ⎘